Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?

Abstract

Purpose of review: This review aims to describe the current understanding of neuroinflammation in neurodegeneration and evaluate the value of various anti-inflammatory treatments. Recent findings: Inflammation plays important roles in common disease such as dementia and depression. Underlying mechanisms including the role of inflammasomes in these diseases have been recently described. Interventions using [OMEGA]-3 polyunsaturated fatty acids, NSAIDs and targeted antagonists (e.g., etanercept) show no convincing clinical efficacy in inflammation-associated depression, cognitive decline and dementia. Summary: Therapeutic targeting of inflammation appears to be relevant in brain conditions characterized by neuroinflammation and neurodegeneration, although published anti-inflammatory interventions have shown no relevant clinical efficacy. Newly described pharmacological targets in the neuroinflammation pathways may not only offer a more profound understanding of the underlying pathophysiology but also raise hope for the development of novel pharmacological agents.